COCP — Cocrystal Pharma, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1412486 ·
Last close
$1.01
Market Cap
$19.46M
52W High
$2.03
52W Low
$0.76
ADV30
34,198
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 105,000 — -3,489,000 -3,444,000 6,773,000 4,873,000 4,098,000
Jun 2026 105,000 — -3,184,000 -3,164,000 4,649,000 2,169,000 3,605,000
Mar 2026 225,000 — -2,356,000 -2,299,000 7,426,000 4,685,000 3,310,000
Dec 2025 0 — -2,481,000 -2,426,000 9,712,000 7,025,000 3,381,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,954,000
Investing CF
$-12,000
Financing CF
$1,032,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-347,712,000
Inventory
—
Receivables
$736,000
ST Investments
—
EBIT TTM
$-10,110,000
Pretax Income TTM
$-9,938,000
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$330,000
EBITDA
$-10,060,000
Free Cash Flow
$-4,318,750
Enterprise Value
$23,058,368
Total Cash
$2,169,000
Total Debt
$1,341,000
Shares Out
19,263,200
Trailing EPS
$-0.75
Book Value
$0.08
ROE
-311.7%
ROA
-96.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -9,019,000 -8,831,000 9,712,000 3,381,000 6,331,000 -8,192,000
Dec 2024 0 -17,878,000 -17,504,000 13,456,000 3,933,000 9,523,000 -16,485,000
Dec 2023 0 -21,159,000 -17,984,000 31,259,000 4,875,000 26,384,000 -14,666,000
Dec 2022 0 -18,137,000 -38,837,000 40,840,000 1,273,000 39,567,000 -21,435,000

TTM Snapshot

Revenues TTM
$330,000
NetIncome TTM
$-9,938,000
OpCashFlow TTM
—
Assets (Latest)
$4,649,000
Forward EPS
$-0.58

Peers — same industry

TickerNameMarket CapLastDaily %
IGC IGC Pharma, Inc. $19.43M $0.19 —
ATOS ATOSSA THERAPEUTICS, INC. $18.96M $1.90 —
EDSA Edesa Biotech, Inc. $18.90M $1.96 —
CELU Celularity Inc $18.53M $0.57 —
CUE Cue Biopharma, Inc. $20.56M $2.83 —

News headlines (Yahoo Finance, 1h cache)

COCP: Phase 1b Norovirus Challenge Study Results Near Year-End 2026
2026-11-18 12:13 · Yahoo
Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
2026-11-15 12:00 · Yahoo
Cocrystal Pharma’s new CEO hopes to crack the norovirus code
2026-09-15 12:56 · Yahoo
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
2026-09-09 11:00 · Yahoo
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
2026-08-31 15:39 · Yahoo
COCP: $5 Million Private Placement with OPKO Health
2026-08-20 11:20 · Yahoo
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
2026-08-17 15:17 · Yahoo
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
2026-08-03 11:00 · Yahoo
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
2026-03-31 12:00 · Yahoo
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate
2026-04-04 12:57 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.